With the time-course of CHX treatment, the expression of HDAC1 in HL-60, K562, and BMCs in remission AML was gradually downregulated in comparison to that of HL-60/ADM and K562/A02 cells in refractory AML. This evidence concerns the gene HDAC1 and acute myeloid leukemia.